ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $537,372 | -38.8% | 101,200 | +9.9% | 0.00% | -100.0% |
| Q2 2023 | $877,713 | -13.4% | 92,100 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,013,100 | -32.7% | 92,100 | -9.4% | 0.00% | 0.0% |
| Q4 2022 | $1,505,160 | -19.5% | 101,700 | +4.0% | 0.00% | 0.0% |
| Q3 2022 | $1,869,000 | +23.2% | 97,800 | +37.4% | 0.00% | 0.0% |
| Q2 2022 | $1,517,000 | +32.4% | 71,200 | +19.7% | 0.00% | 0.0% |
| Q1 2022 | $1,146,000 | +0.1% | 59,500 | +7.8% | 0.00% | 0.0% |
| Q4 2021 | $1,145,000 | -13.2% | 55,200 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,319,000 | -12.4% | 55,200 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,506,000 | -7.4% | 55,200 | -1.8% | 0.00% | 0.0% |
| Q1 2021 | $1,626,000 | +137.7% | 56,200 | +131.3% | 0.00% | – |
| Q4 2020 | $684,000 | +9.6% | 24,300 | +14.1% | 0.00% | – |
| Q3 2020 | $624,000 | -3.1% | 21,300 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $644,000 | – | 21,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |